Department of Gynecology, Gansu Provincial Maternity and Child-Care Hospital, Qilihe, Lanzhou, Gansu, China.
Eur Rev Med Pharmacol Sci. 2020 Jan;24(2):591-603. doi: 10.26355/eurrev_202001_20035.
Ovarian cancer (OC) is a common tumor in women, and the development of chemoresistance is the major obstacle to its treatment. Long non-coding RNAs (LncRNAs) have been linked to chemoresistance in many cancers. However, the function of lncRNA urothelial carcinoma associated1 (UCA1) in paclitaxel (PTX) resistance of OC is not well elucidated.
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of UCA1, microRNA-654-5p (miR-654-5p) and salt inducible kinase 2 (SIK2). Cell PTX resistance and proliferation were evaluated by 3-(4, 5-dimethyl-2 thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) assay. The abilities of apoptosis, migration and invasion were measured by Flow cytometry and Transwell assays, respectively. Dual-luciferase reporter assay was used to verify the interaction among UCA1, miR-654-5p and SIK2. Besides, Western blot analysis was performed to assess the protein level of SIK2.
UCA1 was markedly upregulated in OC tissues and PTX-resistant OC cells. Silencing of UCA1 restrained the PTX resistance, reduced the proliferation, migration, invasion and enhanced the apoptosis of PTX-resistant OC cells. MiR-654-5p could be sponged by UCA1, and the inhibitory effect of its overexpression on the progression of PTX-resistant OC cells could be reversed by overexpressed-UCA1. Moreover, SIK2 was a target of miR-654-5p. Silencing of SIK2 could hinder the PTX resistance and suppress the progression of PTX-resistant OC cells, while miR-654-5p inhibitor could invert this inhibitory effect. Also, the expression of SIK2 was regulated by miR-654-5p and UCA1 expression.
LncRNA UCA1 plays an active role in PTX resistance of OC and is crucial to maintain the development of PTX resistance in OC, which provides a new therapeutic target for the study of OC chemoresistance.
卵巢癌(OC)是女性常见的肿瘤,化疗耐药的发展是其治疗的主要障碍。长链非编码 RNA(lncRNA)与许多癌症的化疗耐药有关。然而,尿路上皮癌相关 1(UCA1)lncRNA 在 OC 紫杉醇(PTX)耐药中的作用尚不清楚。
采用实时定量聚合酶链反应(qRT-PCR)检测 UCA1、microRNA-654-5p(miR-654-5p)和盐诱导激酶 2(SIK2)的表达。通过 3-(4,5-二甲基-2 噻唑基)-2,5-二苯基-2-H-四唑溴盐(MTT)试验评估细胞对 PTX 的耐药性和增殖能力。通过流式细胞术和 Transwell 测定分别测量细胞凋亡、迁移和侵袭能力。双荧光素酶报告基因实验验证 UCA1、miR-654-5p 和 SIK2 之间的相互作用。此外,采用 Western blot 分析检测 SIK2 蛋白水平。
UCA1 在 OC 组织和 PTX 耐药 OC 细胞中明显上调。沉默 UCA1 可抑制 PTX 耐药,减少细胞增殖、迁移、侵袭,促进 PTX 耐药 OC 细胞凋亡。miR-654-5p 可与 UCA1 结合,过表达 miR-654-5p 对 PTX 耐药 OC 细胞进展的抑制作用可被过表达-UCA1 逆转。此外,SIK2 是 miR-654-5p 的靶基因。沉默 SIK2 可阻碍 PTX 耐药并抑制 PTX 耐药 OC 细胞的进展,而 miR-654-5p 抑制剂可逆转这种抑制作用。此外,SIK2 的表达受 miR-654-5p 和 UCA1 表达的调节。
lncRNA UCA1 在 OC 的 PTX 耐药中发挥积极作用,对维持 OC 中 PTX 耐药的发展至关重要,为 OC 化疗耐药的研究提供了新的治疗靶点。